Rameda’s 2Q net income rises to EGP 101 mn on stronger gross margins

EGX-listed Rameda’s net income rose 1.7% y-o-y to EGP 101 mn in 2Q 2026, while revenues increased 9.4% to EGP 1.05 bn, according to the pharma company’s latest earnings release (pdf). Revenue growth was broad-based, led by a 68% jump in domestic tender sales to EGP 92 mn and a 36% increase in exports to EGP 71 mn, while private sales grew 5.3% to EGP 819 mn.

The drivers: Tender volumes surged 90% y-o-y, while export volumes rose 22%, with export growth supported by stronger sales to Iraq and Yemen and new contributions from Jordan and Afghanistan. Private sales continued to grow despite a 23% decline in reported volumes, which largely reflected pack-size changes, API supply restrictions, regulatory requirements for some injectables, and temporary shortages of outsourced products, rather than weaker underlying demand.

(** Tap or click the headline above to read this story with all of the links to our background as well as external sources.)